Germany Vaccine Market Size & Outlook, 2025-2033
Related Markets
Germany vaccine market highlights
- The Germany vaccine market generated a revenue of USD 3,841.8 million in 2024 and is expected to reach USD 6,334.4 million by 2033.
- The Germany market is expected to grow at a CAGR of 5.5% from 2025 to 2033.
- In terms of segment, viral vaccines was the largest revenue generating indication in 2024.
- Other Indication is the most lucrative indication segment registering the fastest growth during the forecast period.
Vaccine market data book summary
| Market revenue in 2024 | USD 3,841.8 million |
| Market revenue in 2033 | USD 6,334.4 million |
| Growth rate | 5.5% (CAGR from 2025 to 2033) |
| Largest segment | Viral vaccines |
| Fastest growing segment | Other Indication |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Viral Vaccines, Bacterial Vaccines, Cancer Vaccines, Allergy Vaccines, Other Indication |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
Other key industry trends
- In terms of revenue, Germany accounted for 5.7% of the global vaccine market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany vaccine market is projected to lead the regional market in terms of revenue in 2033.
- France is the fastest growing regional market in Europe and is projected to reach USD 3,784.9 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Vaccine Market Scope
Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Moderna Inc | View profile | 5600 | 200 Technology Square, Cambridge, MA, United States, 02139 | https://www.modernatx.com |
| BioNTech SE ADR | View profile | 6133 | An der Goldgrube 12, Mainz, RP, Germany, D-55131 | https://www.biontech.de |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Sinovac Biotech Ltd | View profile | 3261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | http://www.sinovac.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | http://www.seruminstitute.com/ |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
Germany vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine market will help companies and investors design strategic landscapes.
Viral vaccines was the largest segment with a revenue share of 65.59% in 2024. Horizon Databook has segmented the Germany vaccine market based on viral vaccines, bacterial vaccines, cancer vaccines, allergy vaccines, other indication covering the revenue growth of each sub-segment from 2021 to 2033.
Presence of research institutions and leading vaccine manufacturers is propelling the Germany vaccine market. In addition, a surge in R&D activities and various strategic initiatives undertaken by leading participants are factors propelling market expansion. Moreover, in November 2022, BioNTech SE & Pfizer, Inc. initiated a phase I trial for a single-dose mRNA-based combination vaccine candidate for COVID-19 and influenza.
In addition, in May 2021, Bavarian Nordic A/S established a collaboration with Dynavax Technologies Corporation, a biopharmaceutical firm dedicated to creating and promoting innovative vaccines. This partnership aims to facilitate the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany.
This proves that Germany is one of the leading research locations, wherein several pharmaceutical & biotechnological companies focus on developing therapies for conditions such as cancer, cardiovascular disorders, & metabolic diseases and applications like drug formulation & development.
Reasons to subscribe to Germany vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Germany vaccine market databook
-
Our clientele includes a mix of vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Germany vaccine market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Germany Recombinant Vaccines - Vaccine Market, 2024 - 2030 (US$M)
Germany Vaccine Market Outlook Share, 2024 & 2033 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
